发明名称 Small molecule inhibitors of N-terminus activation of the androgen receptor
摘要 Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
申请公布号 US9487479(B2) 申请公布日期 2016.11.08
申请号 US200912999035 申请日期 2009.08.24
申请人 The University of British Columbia;British Columbia Cancer Agency Branch 发明人 Sadar Marianne D.;Mawji Nasrin R.;Wang Jun;Andersen Raymond J.;Williams David E.;Leblanc Mike;Yan Lu-Ping
分类号 C07D207/38;A61K31/495 主分类号 C07D207/38
代理机构 Cooley LLP 代理人 Cooley LLP
主权项 1. A compound of the Formula (A): or a salt thereof, wherein: X is C or N; Y is O or S; R1 is H, OH, J, OJ, SJ, or NJJ′, wherein J and J′ are each independently a one to ten carbon linear, branched, non-aromatic cyclic, or aromatic or partially aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, COOR, CONH2, CONHR, CONR2, R, OH, OR, F, Cl, Br, I, NH2, NHR, NR2, CN, SH, SR, SO3H, SO3R, SO2R, OSO3R, and NO2, and wherein R is a linear, or branched saturated and unsubstituted C1-C10 alkyl; R2 is H, an amino acid side chain or a two to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, COOR, CONH2, CONHR, CONR2, R, OH, OR, F, Cl, Br, I, NH2, NHR, NR2, CN, SH, SR, SO3H, SO3R, SO2R, OSO3R, and NO2, and wherein R is a linear, or branched saturated and unsubstituted C1-C10 alkyl, provided that R2 is not a proline or phenylalanine side chain; R3 is H, OH, OG, SG, NGG′ or a one to ten carbon linear, branched, or non-aromatic cyclic, or aromatic or partially aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein G and G′ are each independently a one to ten carbon linear, branched, non-aromatic cyclic, or aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group and wherein the optional substituent is selected from one or more of: oxo, COOH, OH, COOR, CONH2, CONHR, CONR2, R, F, Cl, Br, I, NH2, CN, SH, SO3H, and NO2, wherein R is an unsubstituted C1-C10 alkyl; and R4 and R6 are each independently H, an amino acid side chain or a one to ten carbon linear, branched, aromatic or partially aromatic cyclic, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, OR, R, F, Cl, Br, I, NH2, NHR, NR2, CN, SH, SR, SO3H, SO3R, SO2R, OSO3R, and NO2, and wherein R is an unsubstituted C1-C10 alkyl, provided that both R4 and R6 are not H and provided that neither R4 or R6 are:andprovided that neither R4 or R6 is a proline side chain; R5 is H, an amino acid side chain or a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, CONH2, OH, F, Cl, Br, I, NH2, SO3H, and NO2, provided that R5 is not a proline or phenylalanine side chain; and is a double bond; and provided that the compound is not:
地址 Vancouver, BC CA